Peptidyl-prolyl cis/trans isomerase NIMA-interacting 1 as a therapeutic target in hepatocellular carcinoma

Biological and Pharmaceutical Bulletin

Volumn 38, Issue 7, 2015, Pages 975-979

  Kim, Garam ^a   Kim, Jin Young ^a   Choi, Hong Seok ^a  

^a Chosun University   (South Korea)

Author keywords

Hepatitis B viral protein; Hepatocellular carcinoma; Never in mitosis A (NIMA) related kinase 6; Peptidyl prolyl cis trans isomerase NIMA interacting 1; catenin

Indexed keywords

HEPATITIS B VIRUS X PROTEIN; PEPTIDYLPROLYL ISOMERASE PIN1; NIMA-INTERACTING PEPTIDYLPROLYL ISOMERASE; PEPTIDYLPROLYL ISOMERASE; TRANSACTIVATOR PROTEIN;

APOPTOSIS; ARTICLE; CELL CYCLE REGULATION; CELL PROLIFERATION; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; METASTASIS; MITOSIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; PROTEIN FUNCTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR INVASION; ANIMAL; LIVER TUMOR; METABOLISM; PATHOLOGY;

ANIMALS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; MITOSIS; NEOPLASM INVASIVENESS; PEPTIDYLPROLYL ISOMERASE; TRANS-ACTIVATORS;

EID: 84936752382     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b15-00245     Document Type: Article

References (56)

1. Vineis P, Wild CP. Global cancer patterns: causes and prevention. Lancet, 383, 549-557 (2014).
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin., 61, 69-90 (2011).
3. Coleman WB. Mechanisms of human hepatocarcinogenesis. Curr. Mol. Med., 3, 573-588 (2003).
4. Wulf G, Finn G, Suizu F, Lu KP. Phosphorylation-specific prolyl isomerization: is there an underlying theme? Nat. Cell Biol., 7, 435-441 (2005).
5. Lu KP, Zhou XZ. The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease. Nat. Rev. Mol. Cell Biol., 8, 904-916 (2007).
6. Ryo A, Nakamura M, Wulf G, Liou YC, Lu KP. Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC. Nat. Cell Biol., 3, 793-801 (2001).
7. Pang R, Yuen J, Yuen MF, Lai CL, Lee TK, Man K, Poon RT, Fan ST, Wong CM, Ng IO, Kwong YL, Tse E. PIN1 overexpression and beta-catenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma. Oncogene, 23, 4182-4186 (2004).
8. Pekow JR, Bhan AK, Zheng H, Chung RT. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer, 109, 2490-2496 (2007).
9. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat. Rev. Cancer, 11, 85-95 (2011).
10. Lu Z, Hunter T. Prolyl isomerase Pin1 in cancer. Cell Res., 24, 1033-1049 (2014).
11. Coleman TR, Dunphy WG. Cdc2 regulatory factors. Curr. Opin. Cell Biol., 6, 877-882 (1994).
12. Nigg EA. Cyclin-dependent protein kinases: key regulators of the eukaryotic cell cycle. BioEssays, 17, 471-480 (1995).
13. Hutchins JR, Clarke PR. Many fingers on the mitotic trigger: posttranslational regulation of the Cdc25C phosphatase. Cell Cycle, 3, 40-45 (2004).
14. Lavoie SB, Albert AL, Vincent M. Unexpected roles of the peptidyl-prolyl cis/trans isomerase Pin1. Med. Sci., 19, 1251-1258 (2003).
15. Lu KP, Hanes SD, Hunter T. A human peptidyl-prolyl isomerase essential for regulation of mitosis. Nature, 380, 544-547 (1996).
16. Osmani SA, Pu RT, Morris NR. Mitotic induction and maintenance by overexpression of a G2-specific gene that encodes a potential protein kinase. Cell, 53, 237-244 (1988).
17. Pu RT, Osmani SA. Mitotic destruction of the cell cycle regulated NIMA protein kinase of Aspergillus nidulans is required for mitotic exit. EMBO J., 14, 995-1003 (1995).
18. Zhang B, Zhang H, Wang D, Han S, Wang K, Yao A, Li X. Never in mitosis gene A-related kinase 6 promotes cell proliferation of hepatocellular carcinoma via cyclin B modulation. Oncol. Lett., 8, 1163-1168 (2014).
19. O'Regan L, Fry AM. The Nek6 and Nek7 protein kinases are required for robust mitotic spindle formation and cytokinesis. Mol. Cell. Biol., 29, 3975-3990 (2009).
20. Jee HJ, Kim AJ, Song N, Kim HJ, Kim M, Koh H, Yun J. Nek6 overexpression antagonizes p53-induced senescence in human cancer cells. Cell Cycle, 9, 4703-4710 (2010).
21. Chen J, Li L, Zhang Y, Yang H, Wei Y, Zhang L, Liu X, Yu L. Interaction of Pin1 with Nek6 and characterization of their expression correlation in Chinese hepatocellular carcinoma patients. Biochem. Biophys. Res. Commun., 341, 1059-1065 (2006).
22. Brembeck FH, Rosario M, Birchmeier W. Balancing cell adhesion and Wnt signaling, the key role of beta-catenin. Curr. Opin. Genet. Dev., 16, 51-59 (2006).
23. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat. Med., 10, 789-799 (2004).
24. Polakis P. Wnt signaling and cancer. Genes Dev., 14, 1837-1851 (2000).
25. Jung JK, Kwun HJ, Lee JO, Arora P, Jang KL. Hepatitis B virus X protein differentially affects the ubiquitin-mediated proteasomal degradation of beta-catenin depending on the status of cellular p53. J. Gen. Virol., 88, 2144-2154 (2007).
26. Cha MY, Kim CM, Park YM, Ryu WS. Hepatitis B virus X protein is essential for the activation of Wnt/beta-catenin signaling in hepatoma cells. Hepatology, 39, 1683-1693 (2004).
27. Ding Q, Xia W, Liu JC, Yang JY, Lee DF, Xia J, Bartholomeusz G, Li Y, Pan Y, Li Z, Bargou RC, Qin J, Lai CC, Tsai FJ, Tsai CH, Hung MC. Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol. Cell, 19, 159-170 (2005).
28. Benn J, Su F, Doria M, Schneider RJ. Hepatitis B virus HBx protein induces transcription factor AP-1 by activation of extracellular signal-regulated and c-Jun N-terminal mitogen-activated protein kinases. J. Virol., 70, 4978-4985 (1996).
29. Tanaka Y, Kanai F, Ichimura T, Tateishi K, Asaoka Y, Guleng B, Jazag A, Ohta M, Imamura J, Ikenoue T, Ijichi H, Kawabe T, Isobe T, Omata M. The hepatitis B virus X protein enhances AP-1 activation through interaction with Jab1. Oncogene, 25, 633-642 (2006).
30. Doria M, Klein N, Lucito R, Schneider RJ. The hepatitis B virus HBx protein is a dual specificity cytoplasmic activator of Ras and nuclear activator of transcription factors. EMBO J., 14, 4747-4757 (1995).
31. Bouchard MJ, Schneider RJ. The enigmatic X gene of hepatitis B virus. J. Virol., 78, 12725-12734 (2004).
32. Pang R, Lee TK, Poon RT, Fan ST, Wong KB, Kwong YL, Tse E. Pin1 interacts with a specific serine-proline motif of hepatitis B virus X-protein to enhance hepatocarcinogenesis. Gastroenterology, 132, 1088-1103 (2007).
33. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell, 94, 491-501 (1998).
34. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell, 102, 33-42 (2000).
35. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell, 91, 479-489 (1997).
36. Chen Z, Naito M, Hori S, Mashima T, Yamori T, Tsuruo T. A human IAP-family gene, apollon, expressed in human brain cancer cells. Biochem. Biophys. Res. Commun., 264, 847-854 (1999).
37. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med., 3, 917-921 (1997).
38. Guo M, Hay BA. Cell proliferation and apoptosis. Curr. Opin. Cell Biol., 11, 745-752 (1999).
39. Marusawa H, Matsuzawa S, Welsh K, Zou H, Armstrong R, Tamm I, Reed JC. HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J., 22, 2729-2740 (2003).
40. Cheng CW, Chow AK, Pang R, Fok EW, Kwong YL, Tse E. PIN1 inhibits apoptosis in hepatocellular carcinoma through modulation of the antiapoptotic function of survivin. Am. J. Pathol., 182, 765-775 (2013).
41. Ding Q, Huo L, Yang JY, Xia W, Wei Y, Liao Y, Chang CJ, Yang Y, Lai CC, Lee DF, Yen CJ, Chen YJ, Hsu JM, Kuo HP, Lin CY, Tsai FJ, Li LY, Tsai CH, Hung MC. Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. Cancer Res., 68, 6109-6117 (2008).
42. Sieghart W, Losert D, Strommer S, Cejka D, Schmid K, Rasoul- Rockenschaub S, Bodingbauer M, Crevenna R, Monia BP, Peck-Radosavljevic M, Wacheck V. Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. J. Hepatol., 44, 151-157 (2006).
43. Ryo A, Hirai A, Nishi M, Liou YC, Perrem K, Lin SC, Hirano H, Lee SW, Aoki I. A suppressive role of the prolyl isomerase Pin1 in cellular apoptosis mediated by the death-associated protein Daxx. J. Biol. Chem., 282, 36671-36681 (2007).
44. Rahbari NN, Mehrabi A, Mollberg NM, Muller SA, Koch M, Buchler MW, Weitz J. Hepatocellular carcinoma: current management and perspectives for the future. Ann. Surg., 253, 453-469 (2011).
45. Zhang Y, Li J, Cao L, Xu W, Yin Z. Circulating tumor cells in hepatocellular carcinoma: detection techniques, clinical implications, and future perspectives. Semin. Oncol., 39, 449-460 (2012).
46. Ruoslahti E, Giancotti FG. Integrins and tumor cell dissemination. Cancer Cells, 1, 119-126 (1989).
47. Loftus JC, Liddington RC. New insights into integrin-ligand interaction. J. Clin. Invest., 100 (Suppl.), S77-S81 (1997).
48. Sacco R, Leuci D, Tortorella C, Fiore G, Marinosci F, Antonaci S. Transforming growth factor beta1 and soluble Fas serum levels in hepatocellular carcinoma. Cytokine, 12, 811-814 (2000).
49. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature, 390, 465-471 (1997).
50. Feng XH, Derynck R. Specificity and versatility in tgf-beta signaling through Smads. Annu. Rev. Cell Dev. Biol., 21, 659-693 (2005).
51. Kirmaz C, Terzioglu E, Topalak O, Bayrak P, Yilmaz O, Ersoz G, Sebik F. Serum transforming growth factor-beta1 (TGF-beta1) in patients with cirrhosis, chronic hepatitis B and chronic hepatitis C. Eur. Cytokine Netw., 15, 112-116 (2004), corrected.
52. Castilla A, Prieto J, Fausto N. Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy. N. Engl. J. Med., 324, 933-940 (1991).
53. Giannelli G, Bergamini C, Fransvea E, Marinosci F, Quaranta V, Antonaci S. Human hepatocellular carcinoma (HCC) cells require both alpha3beta1 integrin and matrix metalloproteinases activity for migration and invasion. Lab. Invest., 81, 613-627 (2001).
54. Kim MR, Choi HK, Cho KB, Kim HS, Kang KW. Involvement of Pin1 induction in epithelial-mesenchymal transition of tamoxifen-resistant breast cancer cells. Cancer Sci., 100, 1834-1841 (2009).
55. Nakano A, Koinuma D, Miyazawa K, Uchida T, Saitoh M, Kawabata M, Hanai J, Akiyama H, Abe M, Miyazono K, Matsumoto T, Imamura T. Pin1 down-regulates transforming growth factor-beta (TGF-beta) signaling by inducing degradation of Smad proteins. J. Biol. Chem., 284, 6109-6115 (2009).
56. Matsuura I, Chiang KN, Lai CY, He D, Wang G, Ramkumar R, Uchida T, Ryo A, Lu K, Liu F. Pin1 promotes transforming growth factor-beta-induced migration and invasion. J. Biol. Chem., 285, 1754-1764 (2010).